3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
9
Terminated
3
Unknown
2
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
28
Carcinoma, Non-Small-Cell Lung
22
Lung Neoplasms
17
Cholangiocarcinoma
13
Biliary Tract Neoplasms
13
Small Cell Lung Carcinoma
12
Triple Negative Breast Neoplasms
8
Breast Neoplasms
8
Neoplasms
6
Neoplasm Metastasis
5
Liver Neoplasms
5
Urinary Bladder Neoplasms
4
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Carcinoma
4
Non-Muscle Invasive Bladder Neoplasms
3
Gallbladder Neoplasms
3
Colorectal Neoplasms
3
Adenocarcinoma Of Esophagus
3
Pathologic Complete Response
2
Ovarian Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Bile Duct Neoplasms
2
Advanced Biliary Tract Cancer
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Vaccinia
1
SCLC, Limited Stage
1
Resectable Intrahepatic Cholangiocarcinoma
1
Interventions
Cyclophosphamide
21
venetoclax
18
pembrolizumab
16
Dexamethasone
16
fludarabine
14
Cytarabine
13
Gemcitabine
9
pomalidomide
8
Rituximab
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
Immunotherapy, Adoptive
7
selinexor
6
Paclitaxel
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Oxaliplatin
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
durvalumab
×
Clear all
NCT07221253
2026-03-17
AB02
AstraZeneca
Phase 3
Recruiting
1,100 enrolled